Association of outpatient fluoroquinolone prescribing with the National Medical Products Administration announcements of label changes in China.

Hou-Yu ZhaoYexiang SunXi YaoPeng ShenHongbo LinSiyan Zhan

Published in: Expert review of anti-infective therapy (2024)

The label changes issued by the NMPA had no substantial impacts on fluoroquinolone prescribing in the study region in China. Fluoroquinolone prescribing was still highly prevalent for uUTI and AECB and thus requiring further antimicrobial stewardship.

Keyphrases

primary care
adverse drug
healthcare
quality improvement
emergency department